

Johnson & Johnson Innovative Medicine

Selected Novel Therapies - Recent Approvals/Potential Filings*

(2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of October 17, 2023

Novel Therapies APPROVED

Oncology

RYBREVANT (amivantamab)
Non Small Cell Lung Cancer

CARVYKTI (Ciltacabtagene autoleucel)
Relapsed refractory Multiple Myeloma

TECVAYLI (teclistamab)
Relapsed refractory Multiple Myeloma

AKEEGA (niraparib/abiraterone)
Metastatic castration-resistant prostate cancer (mCRPC)

TALVEY (talquetamab)
Relapsed refractory Multiple Myeloma

Novel Therapies PLANNED FILINGS

Immunology

JNJ-2113
Psoriasis

Cardiovascular and Metabolism

RPGR AAV Gene Therapy
X-linked retinitis pigmentosa

Neuroscience

seltorexant
Adjunctive treatment for major depressive disorder with insomnia

Aticaprant
Adjunctive treatment for major depressive disorder

nipocalimab
Generalized Myasthenia Gravis

Oncology

TAR-200 (RIS/gemcitabine)
Bladder Cancer

amivantamab / lazertinib
Non Small Cell Lung Cancer

Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;